What Comes Next for SAC
The criminal prosecution of Mathew Martoma, a former SAC employee, continues, and it raises the intriguing question about whether prosecutors will call anyone from the hedge fund as a witness against...
View ArticleJudge Is Skeptical of S.E.C. Deal With Hedge Fund
Judge Victor Marrero made it clear that he was troubled that SAC Capital did not have to acknowledge wrongdoing to settle insider-trading accusations by the Securities and Exchange Commission.
View ArticleMartoma, Former SAC Employee, Changes Lawyers in Insider Case
Mathew Martoma, the former SAC Capital Advisors portfolio manager facing insider trading charges, has switched lawyers, replacing Charles A. Stillman with Richard M. Strassberg of Goodwin Procter.
View ArticleTrial Date Set for Former SAC Trader in Insider Case
Federal prosecutors have accused Mathew Martoma of making more than $276 million in a combination of illegal profits and avoided losses trading in the shares of the pharmaceutical companies Elan and...
View ArticleLegal Merger Shows Rise in Criminal Defense Status
Stillman & Friedman, a New York firm that has represented some big clients, is combining with Ballard Spahr, an old-line Philadelphia firm.
View ArticleWhat Comes Next for SAC
The criminal prosecution of Mathew Martoma, a former SAC employee, continues, and it raises the intriguing question about whether prosecutors will call anyone from the hedge fund as a witness against...
View ArticleJudge Is Skeptical of S.E.C. Deal With Hedge Fund
Judge Victor Marrero made it clear that he was troubled that SAC Capital did not have to acknowledge wrongdoing to settle insider-trading accusations by the Securities and Exchange Commission.
View ArticleMartoma, Former SAC Employee, Changes Lawyers in Insider Case
Mathew Martoma, the former SAC Capital Advisors portfolio manager facing insider trading charges, has switched lawyers, replacing Charles A. Stillman with Richard M. Strassberg of Goodwin Procter.
View ArticleTrial Date Set for Former SAC Trader in Insider Case
Federal prosecutors have accused Mathew Martoma of making more than $276 million in a combination of illegal profits and avoided losses trading in the shares of the pharmaceutical companies Elan and...
View Article